4//SEC Filing
Schick Kelly 4
Accession 0001662579-24-000028
CIK 0001662579other
Filed
Mar 7, 7:00 PM ET
Accepted
Mar 8, 7:24 PM ET
Size
12.3 KB
Accession
0001662579-24-000028
Insider Transaction Report
Form 4
Schick Kelly
Chief People Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2024-03-07−92,000→ 0 totalExercise: $37.46Exp: 2031-01-10→ Common Stock (92,000 underlying) - Award
Stock Option (Right to Buy)
2024-03-07+78,500→ 78,500 totalExercise: $19.00Exp: 2032-02-13→ Common Stock (78,500 underlying) - Award
Stock Option (Right to Buy)
2024-03-07+92,000→ 92,000 totalExercise: $19.00Exp: 2031-01-10→ Common Stock (92,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-03-07−78,500→ 0 totalExercise: $22.71Exp: 2032-02-13→ Common Stock (78,500 underlying)
Footnotes (3)
- [F1]On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- [F2]25% of the shares underlying this option vested and became exercisable on January 11, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.
- [F3]The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022.
Documents
Issuer
C4 Therapeutics, Inc.
CIK 0001662579
Entity typeother
Related Parties
1- filerCIK 0001797388
Filing Metadata
- Form type
- 4
- Filed
- Mar 7, 7:00 PM ET
- Accepted
- Mar 8, 7:24 PM ET
- Size
- 12.3 KB